Fungal dysbiosis is increasingly recognized as a key factor in cancer, influencing tumor initiation, progression, and treatment outcomes. This review explores the role of fungi in carcinogenesis, with a focus on mechanisms such as immunomodulation, inflammation induction, tumor microenvironment remodeling, and interkingdom interactions. Fungal metabolites are involved in oncogenesis, and antifungals can interact with anticancer drug, including eliciting potential adverse effects and influencing immune responses. Furthermore, mycobiota profiles have potential as diagnostic and prognostic biomarkers, emphasizing their clinical relevance. The interplay between fungi and cancer therapies can impact drug resistance, therapeutic efficacy, and risk of invasive fungal infections associated with targeted therapies. Finally, emerging strategies for modulating mycobiota in cancer care are promising approaches to improve patient outcomes.

中文翻译：

---

真菌对癌症发生、进展和治疗反应的影响


真菌菌群失调越来越被认为是癌症的关键因素，影响肿瘤的发生、进展和治疗结果。本文探讨了真菌在致癌作用中的作用，重点关注免疫调节、炎症诱导、肿瘤微环境重塑和界间相互作用等机制。真菌代谢物参与肿瘤发生，抗真菌药可与抗癌药物相互作用，包括引发潜在的不良反应和影响免疫反应。此外，菌群谱具有作为诊断和预后生物标志物的潜力，强调了它们的临床相关性。真菌和癌症疗法之间的相互作用会影响耐药性、治疗效果和与靶向治疗相关的侵袭性真菌感染的风险。最后，在癌症护理中调节菌群的新兴策略是改善患者预后的有前途的方法。